Ranbaxy Purchases Instem’s Preclinical Software Suite
Provantis Preclinical Software Suite Selected to automate R&D Laboratory Processes in India
CONSHOHOCKEN, PA – May 8, 2014 - - Instem, a leading provider of IT solutions to the global early development healthcare market, is pleased to announce that Ranbaxy Laboratories Limited (Ranbaxy) has purchased the Provantis® preclinical software suite to automate laboratory processes at their R&D Headquarters in Gurgaon, India.
Ranbaxy is a research based international pharmaceutical company serving customers in over 150 countries. Ranbaxy develops, manufactures and markets generic, branded generic, value-added and Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates. The company also carries out new, innovative research.
Ranbaxy’s continued focus on research & development has resulted in several regulatory approvals in both developed and emerging markets, including the development of India’s first New Chemical Entity (NCE), Synriam™, a new age cure for Malaria.
- Ranbaxy to implement Provantis 9, the latest version of Instem’s market leading preclinical software solution
- Comprehensive suite of integrated Provantis modules to be deployed, including Inlife, Pathology, Tables
& Statistics, Clinical Pathology, Protocol & Report Assembly
- Provantis to replace in-house developed applications to streamline processes and further improve productivity
- A range of professional services purchased to facilitate quicker, smoother implementation and faster
return on investment
- Provantis software to provide enhanced compliance capabilities
Provantis will be delivering demonstrable efficiency improvements to Ranbaxy at its Gurgaon R&D center in India and will offer enhanced compliance capabilities, integrated reporting and reduced QC burden.
Instem’s VP Global Sales, Europe & Asia, Neil Donaldson, commented “We are delighted to welcome Ranbaxy as our newest client in the Asia Pacific region and look forward to a long and successful partnership. Instem recognizes the increasingly important role that Indian organizations play in the global pharmaceutical market and we are committed to supporting the future growth and development of the Indian R&D community”.
Instem entered the early drug development market in India during 2005 when they welcomed their first Indian customer, Advinus Therapeutics. Instem maintains a physical presence in the region through its office in Pune.
Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals, in developed and emerging markets, many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas.
Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries.
Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company’s commitment to increase penetration and improve access to medicines, across the globe.
For more information, please visit www.ranbaxy.com.
Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.
Meeting clients at the intersection of investment & return™.
Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600
Gary Mitchell (US HQ)